Next Article in Journal
Correlation between Psychosomatic Assessment, Heart Rate Variability, and Refractory GERD: A Prospective Study in Patients with Acid Reflux Esophagitis
Next Article in Special Issue
Association of Atrial Fibrillation Recurrence with Right Coronary Atherosclerosis and Increased Left Arterial Epicardial Fat Following Catheter Ablation—Results of a Multimodality Study
Previous Article in Journal
In Search of Apis mellifera pomonella in Kazakhstan
Previous Article in Special Issue
Focused Ultrasound, an Emerging Tool for Atherosclerosis Treatment: A Comprehensive Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 9
10.3390/life13091861
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inflammatory Markers Used as Predictors of Subclinical Atherosclerosis in Patients with Diabetic Polyneuropathy

by
Adrian Vasile Mureșan
1,2,†,
Alexandru Tomac
3,†,
Diana Roxana Opriș
4,*,
Bogdan Corneliu Bandici
1,*,
Cătălin Mircea Coșarcă
1,5,
Diana Carina Covalcic
1,
Ioana Hălmaciu
6,
Orsolya-Zsuzsa Akácsos-Szász
7,
Flavia Rădulescu
8,9,
Krisztina Lázár
8,
Adina Stoian
10 and
Mariana Cornelia Tilinca
11,12
1
Clinic of Vascular Surgery, Mures County Emergency Hospital, 540136 Targu Mures, Romania
2
Department of Vascular Surgery, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
3
Clinic of Plastic Surgery, Emergency Clinical Hospital Saint Spiridon, 700111 Iasi, Romania
4
Emergency Institute for Cardiovascular Diseases and Transplantation (IUBCVT) of Targu Mures, 540136 Targu Mures, Romania
5
Department of Anatomy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
6
Department of Radiology, Mures County Emergency Hospital, 540136 Targu Mures, Romania
7
Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania
8
Clinical Department of Endocrinology, Mures County Emergency Hospital, 540136 Targu Mures, Romania
9
Department of Scientific Research Methodology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
10
Department of Pathophysiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
11
Department of Diabetes, Nutrition and Metabolic Diseases, Mures County Emergency Hospital, 540136 Targu Mures, Romania
12
Department of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Life 2023, 13(9), 1861; https://doi.org/10.3390/life13091861
Submission received: 1 August 2023 / Revised: 25 August 2023 / Accepted: 1 September 2023 / Published: 3 September 2023
(This article belongs to the Special Issue Atherosclerosis: From Subclinical Diagnosis to Interventional Treatment)
Browse Figures
Versions Notes

Abstract

:
Background: peripheral arterial disease (PAD) is identified late in diabetic patients because, in the majority of cases, it is associated with diabetic peripheral neuropathy, resulting in little or no symptoms, or symptoms that are completely neglected. Methods: In this study were enrolled all patients over 18 years of age, with diabetes mellitus type II for more than a year with poor glycemic control, diagnosed with diabetic polyneuropathy admitted to the Diabetology Department, Emergency County Hospital of Targu Mures, Romania between January 2020 and March 2023. We divided the patients into two groups, based on the presence or absence of subclinical atherosclerosis in the lower limb, named “SA” and “non-SA”. Results: Patients in the SA group were older (p = 0.01) and had a higher incidence of IHD (p = 0.03), history of MI (p = 0.02), and diabetic nephropathy (p = 0.01). Moreover, patients with subclinical atherosclerosis had a higher BMI (p < 0.0001) and a longer duration of diabetes (p < 0.0001). Among all patients, the systemic inflammatory markers, MLR (r = 0.331, p < 0.001), NLR (r = 0.517, p < 0.001), PLR (r = 0.296, p < 0.001), SII (r = 0.413, p < 0.001), as well as BMI (r = 0.241, p < 0.001) and HbA1C (r = 0.489, p < 0.001), demonstrated a strong positive correlation with the diabetes duration. The multivariate logistic regression analysis showed that older patients (OR: 2.58, p < 0.001), the male gender (OR: 2.30, p = 0.006), a higher baseline levels of BMI (OR: 7.71, p < 0.001), and the duration of diabetes (OR: 8.65, p < 0.001) are predictors of subclinical atherosclerosis in DN patients. Additionally, the high baseline levels of all systemic inflammatory markers (for all: p < 0.001) and poor diabetes management (OR: 10.4, p < 0.001 for HbA1C; OR: 10.78, p < 0.001 for admission glucose) are independent predictors of SA. Conclusions: the inflammatory markers, NLR, MLR, PLR, and SII, being cheap and easy to collect in routine medical practice from the standard blood tests, could be an important step in predicting vascular outcomes in diabetic patients and the disease’s progression, playing a key role in follow-up visits in type-2 diabetic patients and PAD patients.

1. Introduction

A continuously aging population and their continuous variations in alimentation patterns and day-to-day life culminate in an increase in the frequency, disability, and mortality rates of diabetes, the primary causes of which are defective insulin secretion or insufficient feedback to insulin, having negative consequences on the world’s public health and demanding tremendous efforts in changing and adapting the health policies to this progressively demanding situation. The number of people suffering from diabetes around the world has increased by almost 300% in the last 30 years [1]. Furthermore, in 2019, almost 9.3% of the adult population was suffering from diabetes, which equates to 463 million people’s lives being harmed daily by this “silent killer” [2].
With an estimated global population of over 200 million people [3], peripheral arterial disease (PAD) is characterized by the presence of atherosclerotic plaques in the arteries of the lower limbs. Diabetes mellitus (DM) is a key risk factor for the development of PAD and an independent predictor of low-extremity amputations and death in PAD patients [4,5,6]. Following the Framingham study, it is known that DM is a significant risk factor for PAD [7], and the damaged region is more widespread and clinically much more severe in DM patients [4,5,6,7]. Furthermore, PAD patients with diabetes exhibit infrainguinal and crural Trans-Atlantic Inter-Society Consensus (TASC) II C/D lesions, which have a highly unsatisfactory evolution with poor long-term results [7].
PAD is diagnosed late in diabetic patients because, in the majority of cases, it is accompanied by diabetic peripheral neuropathy, resulting in few symptoms or being completely neglected. Because PAD is asymptomatic in its early stages and results in reduced pain perception in diabetic patients due to peripheral neuropathy that affects sensory feedback [8], it is predicted that only 20–30% of those with DM develop PAD [9].
When it comes to the mechanism of PAD in diabetic patients, it associates the pathological states encountered in DM (hyperglycemia, insulin resistance) with those encountered in PAD (vascular inflammation, endothelial cell dysfunction, anomalies in blood cells, including smooth muscle cells and platelets), all of which contribute to the increased plaque burden and its instability, as well as the disease’s and treatment’s increased complexity [10,11].
A constant level of elevated blood glucose and insulin resistance can cause significant vascular deterioration, resulting in neuropathy, nephropathy, retinopathy, and cardiovascular diseases, including a course of peripheral arterial disease; they all contribute to both the mortality and morbidity of diabetes mellitus type 1 and 2, [12], a diabetic patient having a risk up to three times higher of premature death with their life expectancy being shorter by 8 years [13]. Diabetic peripheral neuropathy is the most prevalent chronic neurological consequence [14], affecting half of all patients, with distal symmetric polyneuropathy being the most common manifestation.
In recent years, there has been an increase in scientific research that emphasizes the standard blood testing that can provide data about certain diseases [15,16]. There is evidence that neutrophile-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) predict the progression of complications in diabetic patients [17,18,19,20,21,22,23], as well as their function in predicting cardiovascular events [13,14,15,16]. The purpose of this study is to evaluate the association between inflammation and, by using WBC-derived inflammatory biomarkers, to try to predict subclinical atherosclerosis in patients with peripheral diabetic neuropathy.

2. Materials and Methods

2.1. Study Design

In this observational, retrospective study were enrolled all patients over 18 years of age, with diabetes mellitus type II for over one year, diagnosed with diabetic polyneuropathy admitted to the Diabetology Department, Emergency County Hospital of Targu Mures, Romania between January 2020 and March 2023. Patients with oncological disease, hematological disease, history of major surgery in the last 3 months, and symptomatic atherosclerosis of the lower limb were excluded. Based on the diagnosis of subclinical atherosclerosis in the lower limb, we divided the patients into two groups with and without subclinical atherosclerosis named “SA” and “non-SA”.

2.2. Data Collection

We extracted, from the hospital’s electronic database, the demographic data, comorbidities, and laboratory analyses on the day of admission: hemoglobin level, hematocrit level, number of neutrophils, monocytes, platelets, lymphocytes, glucose level, total cholesterol level, triglyceride level, blood urea nitrogen (BUN), creatinine, and glomerular filtration rate (GFR).

2.3. Study Outcomes

The primary outcomes were the risk of subclinical atherosclerosis at the level of the lower limb in patients with diabetic polyneuropathy with poor glycemic control. Subclinical atherosclerosis at the level of the lower limb was quantified as any 50–70% stenosis at the level of the superficial femoral artery or the popliteal artery found in computed tomography angiography exams.

2.4. Statistical Analysis

SPSS for Mac OS version 28.0.1.0 was used for statistical analysis (SPSS, Inc., Chicago, IL, USA). Chi-square tests were used to assess the associations of the ratios with category factors, while Student’s t- or Mann–Whitney tests were used to assess differences in continuous variables. The ROC curve analysis was used to determine the appropriate BMI, admission glucose level, HbA1C, NLR, MLR, PLR, and SII cut-off values based on the Youden index (Youden Index = sensitivity + specificity − 1, ranging from 0 to 1). To identify independent predictors of SA in patients with DN, a multivariate logistic regression analysis using variables with p < 0.1 was undertaken.

3. Results

During the research period, 198 patients met the criteria and were enrolled in this study, with an average age of 64.36 ± 10.18, of which 105 patients were female (53.03%), and 71 patients (36.36%) had subclinical atherosclerosis in the lower limb. Moreover, the patients in the SA group were older (p = 0.01). Regarding the comorbidities and risk factors, as we see in Table 1, there was a greater incidence of IHD (p = 0.03), history of MI (p = 0.02), as well as diabetic nephropathy (p = 0.01) in the second group of patients. Moreover, patients with subclinical atherosclerosis had a higher BMI (p < 0.0001) and a longer duration of diabetes (p < 0.0001).
In addition, statistically significant variations in laboratory analyses were found between the two groups. As a result, we recorded higher values for HbA1C (p < 0.0001), admission glucose (p < 0.0001), cholesterol (p < 0.0001), creatinine (p = 0.02), neutrophil (p = 0.02), and all the WBC-derived inflammatory markers (all p < 0.0001). On the other hand, we recorded a low level of monocytes (p = 0.03), lymphocytes (p < 0.0001), ALT (p = 0.04), and AST (p = 0.007).
Among all patients, systemic inflammatory markers, MLR (r = 0.331, p < 0.001), NLR (r = 0.517, p < 0.001), PLR (r = 0.296, p < 0.001), SII (r = 0.413, p < 0.001), as well as BMI (r = 0.241, p < 0.001) and HbA1C (r = 0.489, p < 0.001), exhibited a strong positive correlation with the duration of diabetes, as seen in Figure 1.
When analyzing the ROC curve, as seen in Figure 2, all inflammatory markers (for all p < 0.0001), BMI (p < 0.0001), HbA1C (p < 0.0001), duration of diabetes (p < 0.0001), and glucose admission (p < 0.0001) were associated with subclinical atherosclerosis. Moreover, Table 2 presents the optimal cut-off value of the above-mentioned markers, as well as the characteristics.
The multivariate logistic regression analysis showed that older patients (OR: 2.58, p < 0.001), the male gender (OR: 2.30, p = 0.006), a higher baseline value of BMI (OR: 7.71, p < 0.001), and the duration of diabetes (OR: 8.65, p < 0.001) are predictors of subclinical atherosclerosis in DN patients (Table 3). Additionally, the high baseline level of all systemic inflammatory markers (for all p < 0.001) and poor controlling status of diabetes (OR: 10.4, p < 0.001 for HbA1C; OR: 10.78, p < 0.001 for admission glucose) are independent predictors of SA.

4. Discussion

The main result of this study is that the total number of neutrophils, monocytes, lymphocytes, and platelets can predict AS in diabetic patients with PN. Also, our study found that older patients (p < 0.001), the male gender (p = 0.006), the presence of cardiac comorbidities (for all: p < 0.05), diabetes duration (p < 0.001), high BMI values (p < 0.001), and poor diabetes control (p < 0.001) are associated with AS in patients with PN.
The tissue stress generated by persistent hyperglycemia is a major cause of microvascular disease. Major clinical studies, such as the UK Prospective Diabetes Study (UKPDS) and the Diabetes Control of Complications Trial (DCCT), have demonstrated a clear link between microvascular disease and glucose control [24,25]. Microvascular disease manifests itself most prominently in tissues where glucose uptake is insulin-independent, such as the retina, kidney, and vascular endothelium, where the glucose level is nearly the same as in the blood. The disease’s progression is the result of a combination of oxidative stress induced by superoxide overproduction, direct glucose-mediated endothelium degradation, and the production of sorbitol and advanced glycation end-products caused by continuous hyperglycemia [26].
Inflammation raises the risk of atherosclerosis and thrombosis. CRP (C-reactive protein) has multiple roles in both the evolution of PAD and the abnormal glucose regulation [27]: it increases the production of procoagulant tissue factor, chemotactic substances, and leukocyte adhesion molecules; it affects the vascularization by prohibiting the endothelial nitric oxide synthase which normally produces nitric oxide (NO) by switching to a different pathway which is phosphoinositol-3-kinase dependent [8,10]; it alters the fibrinolysis by blocking the formation of PAI-1 (plasminogen activator inhibitor). These changes increase the probability of diabetic vascular walls developing atherosclerosis [28].
DM, which is accompanied by high levels of proinflammatory cytokines (TNF, IL-6) [29,30], promotes the attachment of leukocytes and platelets to the endothelial wall through the nuclear factor (NF) and endothelial cell adhesion molecules, resulting in some ideal conditions for thrombus formation [10,28,31].
Diabetic retinopathy (DR), which is classified into two stages, non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), is a significant complication of diabetes that is the leading cause of vision loss in working-age populations.
Inflammation has a critical role in the evolution of diabetic retinopathy. Recurrent low-grade inflammation has been observed in diabetic patients with DR [32], with leukostasis being acknowledged to play an important role in the early stages of DR but also being related to endothelial damage. Schroder et al. were the first to report granulocyte and monocyte obstruction of the retinal microvasculature [33]. In diabetic patients, there was an increase in leukocyte adhesion and the expression of leukocyte b2-integrins CD11a, CD11b, and CD18 [34], but also, high levels of endothelial cell adhesion molecules such as intercellular adhesion molecule-1(ICAM-1), vascular cell adhesion molecule (VCAM-1), and selectins (E-selectin) were seen in diabetic patients [35,36], the last two being also correlated with the severity of DR [37]. According to studies, chemokines that influence the attraction and activation of leukocytes, such as monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alfa), and MIP-1beta, are elevated in diabetes [38]. Moreover, there were findings about the correlation between the high levels of inflammatory cytokines (tumor necrosis factor alpha—TNF-alfa, interleukin 6—IL-6, IL-8, IL-1beta) and the severity of the DR [39,40]. The pathophysiology of diabetic retinopathy is very complicated, involving hyperglycemia, through several metabolic pathways, retinal microvasculopathy, and retinal degeneration, with enhanced mitochondrial fragmentation and cell apoptosis, as well as inflammation.
Diabetic nephropathy (DN), a very well-known consequence of long-term diabetes linked to its rising morbidity and mortality, is induced by the glomerulus’ chronic suffering caused by hypertension and hyperglycemia and is typically characterized by the thickening of the basement membrane, atrophy, and arteriosclerosis, resulting in the loss of renal function over time [41]. With the rise of people being diagnosed with diabetes, DN’s prevalence is also expected to grow [42,43].
DN was not first thought to be an inflammatory condition, but Tavafi [44] demonstrated the role of inflammation in its evolution. With more evidence in the recent years regarding the role of IL-1, IL-18, and IL-6 in the progression of DN [45,46,47], it has been reported that inflammation is an important part of initiating and continuing the nephropathy’s evolution, with monocytes, macrophages, and leukocytes being part of its pathogenesis [47].
Inflammation could be possibly activated by a biochemical, metabolic, or hemodynamic process present in DN [48], with the IL-18, IL-6, TNF-alfa, and TNF-beta1 being at high levels in the circulating blood supply [30]; their role in DN’s evolution has already been proved, with other studies reporting that their levels rise with the aggravation of the disease [49]. Meanwhile, studies show that the slowing down of the inflammatory process had a protective effect on the disease’s capacity to progress [50], reiterating the role of inflammation in nephropathy’s evolution. Aside from the proinflammatory and fibrogenic cytokines that harm the renal structure, there are also high levels of chemoattractant cytokines and adhesion molecules, all of this being important because they attract circulating leukocytes and facilitate their migration into the kidney tissue. With the last mentioned being also capable of producing cytokines and other inflammatory key substances, it contributes to the continuously developing inflammatory processes in the renal structures [44].
The most common type of neuropathy encountered in daily medical practice is distal symmetric sensorimotor polyneuropathy (DPN), which is asymptomatic in up to 50% of patients and affects both small and big fibers. It can consist of a wide range of clinical disorders, such as cranial nerve palsies, autonomic dysfunction, and mononeuropathies.
Clinical studies have recently revealed that long-term low-intensity inflammation plays an undeniably key role in DPN. Some studies on DPN patients without and with pain showed that the latter group had a higher level of inflammation as indicated by inflammatory markers and cytokines [51]. In another study performed by Magrinelli et al. [52], it was found that high levels of IL-6 and IL-10 (recognized as anti-inflammatory cytokines) were found in some DPN patients, corresponding to some anomalies in large nerve fibers. At the same time, it appears that there is a certain association between high levels of IL-6, IL-1, transforming growth factor-beta, and tumor necrosis factor and the evolution of nerve degeneration in DPN [53].
Nuclear factor-2 erythroid-related factor 2 which controls the management of detoxifying and antioxidant enzymes was found to be low in DPN patients, while the nuclear factor-kappa light chain enhancer of B cells, implicated in proinflammatory cytokines was reported as high; this situation could result in progressive inflammation, increased oxidative stress, poor blood-nerve supply, nerve harm and apoptosis, and pain hypersensitivity [54].
After a study in the population-based cross-sectional Cooperative Health Research in the region of Augsburg F4, it was brought to our attention that the levels of some cytokines covering IL-1 receptor antagonist (IL-1RA) were affirmatively associated with DPN [54].
Herder et al. [55] reported that systemic inflammation was able to predict the onset and progression of DPN over 6.5 years, that increased levels of IL-6, soluble intracellular adhesion molecule-1 (ICAM-1), plasma high-sensitivity C-reactive protein, TNF-alfa and IL-1RA, and low levels of adiponectin were associated with DPN, while elevated IL-1RA and ICAM-1 are connected to its evolution. Herder et al. also reported that vascular cell adhesion molecule-1, chemokines, and E-selectin are at high levels when it comes to DPN and its progression, and they advocated using IL-1RA and ICAM-1 as biomarkers to predict the DPN’s evolution in diabetic patients.
Between the two groups, we had a greater significant statistic mean age difference (66.80 ± 10.13), this being reported also by Eschol J et al. [55] and Lekshmi [56], who found that age is a predictor for PAD; therefore, PAD prevalence was positively correlated with age. Senior patients are at a higher risk of vascular illnesses because they do not pay so much attention to their health. Many researchers have focused on the underdiagnosis of PAD in diabetic patients [57].
Meanwhile, the PAD group had more patients with a history of myocardial infarction and ischemic heart disease (15.57% and 63.88% vs. 5.55% and 48.41%, p = 0.02 and p = 0.03), with PAD patients having a higher rate of comorbidities. A strong relationship between the previous history of cardiovascular disease and PAD was reported by Merino et al. [58] and by Velescu et al. [59], where PAD was related to an increased risk of cardiovascular death, major macrovascular events, and myocardial infarction.
In the scientific medical literature, significant attention has been given to hematological indices such as NLR (neutrophil-to-lymphocyte ratio), MLR (monocyte-to-lymphocyte ratio), and PLR (platelet-to-lymphocyte ratio), along with derived indices like SII (systemic immune-inflammation index), SIRI (systemic immune-inflammation response index), and AISI (all-inflammatory index). An analysis of recently published articles reveals that among these inflammatory markers, NLR, MLR, PLR, and SII have emerged as valuable predictors of vascular disease. Numerous works have highlighted their predictive potential in this context [60,61,62,63,64,65,66,67,68,69,70,71,72,73].
Recently, Wachsmann et al. [74,75] emphasized the importance of diabetes control and HbA1C in the favorable evolution one year after endovascular treatment in patients diagnosed with critical limb ischemia; much more recently in 2022, they published a systematic review in which they demonstrated the role of leukotrienes in cardiovascular atherosclerotic pathology.
The main strength of this study is the large number of systemic inflammatory markers analyzed in the detection of subclinical atherosclerosis in diabetic patients with diabetic polyneuropathy. In contrast, this study has certain limitations. Because this was a monocentric retrospective study, we urge that multicentric investigations with the tracking of inflammatory markers in dynamics be conducted in the future to improve the accuracy of their prognostic potential. Also, another limitation is the monitoring of the presence of subclinical atherosclerosis during hospitalization; in the future, we propose to monitor the patients in the long term and to quantify, with the help of arterial Doppler ultrasound and through regular checks every six months, the degree and progression of the atherosclerotic damage.

5. Conclusions

Given the data from our study and all the other scientific research that has examined this topic, we believe that these inflammatory markers, NLR, MLR, PLR, and SII, which are cheap and easy to collect in everyday medical practice from the routine blood test, could be an important step in predicting vascular outcomes in diabetic patients and the disease’s evolution, playing a key role in follow-up visits in type-2 diabetic patients and PAD patients.

Author Contributions

Conceptualization, A.V.M., A.T. and M.C.T.; methodology, software, and formal analysis, D.R.O. and B.C.B.; validation, all authors; investigation, resources, data curation, C.M.C. and D.C.C.; writing—original draft preparation, I.H. and A.V.M.; writing—review and editing, A.T.; visualization, supervision, project administration, and funding acquisition, A.S., M.C.T., O.-Z.A.-S., F.R. and K.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Mures County Emergency Hospital, 540136, Targu Mures, Romania (protocol code 7157, on 13 March 2020).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data are available based on the request from corresponding authors.

Acknowledgments

This paper was published with the support of the George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139, Targu Mures, Romania, Research Grant number 294/6/14.01.2020. We also express our gratitude to our patients for agreeing to participate in this case report and for contributing to the medical knowledge on this subject.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zheng, Y.; Ley, S.H.; Hu, F.B. Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications. Nat. Rev. Endocrinol. 2018, 14, 88–98. [Google Scholar] [CrossRef] [PubMed]
  2. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [Google Scholar] [CrossRef] [PubMed]
  3. Fowkes, F.G.R.; Rudan, D.; Rudan, I.; Aboyans, V.; Denenberg, J.O.; McDermott, M.M.; Norman, P.E.; Sampson, U.K.A.; Williams, L.J.; Mensah, G.A.; et al. Comparison of Global Estimates of Prevalence and Risk Factors for Peripheral Artery Disease in 2000 and 2010: A Systematic Review and Analysis. Lancet Lond. Engl. 2013, 382, 1329–1340. [Google Scholar] [CrossRef] [PubMed]
  4. Malyar, N.M.; Freisinger, E.; Meyborg, M.; Lüders, F.; Gebauer, K.; Reinecke, H.; Lawall, H. Amputations and Mortality in In-Hospital Treated Patients with Peripheral Artery Disease and Diabetic Foot Syndrome. J. Diabetes Complicat. 2016, 30, 1117–1122. [Google Scholar] [CrossRef]
  5. Humphries, M.D.; Brunson, A.; Hedayati, N.; Romano, P.; Melnkow, J. Amputation Risk in Patients with Diabetes Mellitus and Peripheral Artery Disease Using Statewide Data. Ann. Vasc. Surg. 2016, 30, 123–131. [Google Scholar] [CrossRef]
  6. Freisinger, E.; Malyar, N.M.; Reinecke, H.; Lawall, H. Impact of Diabetes on Outcome in Critical Limb Ischemia with Tissue Loss: A Large-Scaled Routine Data Analysis. Cardiovasc. Diabetol. 2017, 16, 41. [Google Scholar] [CrossRef]
  7. Murabito, J.M.; D’Agostino, R.B.; Silbershatz, H.; Wilson, W.F. Intermittent Claudication. A Risk Profile from The Framingham Heart Study. Circulation 1997, 96, 44–49. [Google Scholar] [CrossRef]
  8. American Diabetes Association. Peripheral Arterial Disease in People with Diabetes. Diabetes Care 2003, 26, 3333–3341. [Google Scholar] [CrossRef]
  9. Marso, S.P.; Hiatt, W.R. Peripheral Arterial Disease in Patients with Diabetes. J. Am. Coll. Cardiol. 2006, 47, 921–929. [Google Scholar] [CrossRef]
  10. Armstrong, E.J.; Rutledge, J.C.; Rogers, J.H. Coronary Artery Revascularization in Patients with Diabetes. Circulation 2013, 128, 1675–1685. [Google Scholar] [CrossRef]
  11. Li, Y.; Woo, V.; Bose, R. Platelet Hyperactivity and Abnormal Ca2+ Homeostasis in Diabetes Mellitus. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1480–H1489. [Google Scholar] [CrossRef]
  12. Fowler, M.J. Microvascular and Macrovascular Complications of Diabetes. Clin. Diabetes 2008, 26, 77–82. [Google Scholar] [CrossRef]
  13. Emerging Risk Factors Collaboration; Di Angelantonio, E.; Kaptoge, S.; Wormser, D.; Willeit, P.; Butterworth, A.S.; Bansal, N.; O’Keeffe, L.M.; Gao, P.; Wood, A.M.; et al. Association of Cardiometabolic Multimorbidity with Mortality. JAMA 2015, 314, 52–60. [Google Scholar] [CrossRef]
  14. Tesfaye, S.; Boulton, A.J.M.; Dickenson, A.H. Mechanisms and Management of Diabetic Painful Distal Symmetrical Polyneuropathy. Diabetes Care 2013, 36, 2456–2465. [Google Scholar] [CrossRef] [PubMed]
  15. Yuan, Q.; Wang, J.; Peng, Z.; Zhou, Q.; Xiao, X.; Xie, Y.; Wang, W.; Huang, L.; Tang, W.; Sun, D.; et al. Neutrophil-to-Lymphocyte Ratio and Incident End-Stage Renal Disease in Chinese Patients with Chronic Kidney Disease: Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J. Transl. Med. 2019, 17, 86. [Google Scholar] [CrossRef]
  16. Azab, B.; Zaher, M.; Weiserbs, K.F.; Torbey, E.; Lacossiere, K.; Gaddam, S.; Gobunsuy, R.; Jadonath, S.; Baldari, D.; McCord, D.; et al. Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Short- and Long-Term Mortality after Non-ST-Elevation Myocardial Infarction. Am. J. Cardiol. 2010, 106, 470–476. [Google Scholar] [CrossRef] [PubMed]
  17. Mertoglu, C.; Gunay, M. Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio as Useful Predictive Markers of Prediabetes and Diabetes Mellitus. Diabetes Metab. Syndr. 2017, 11 (Suppl. S1), S127–S131. [Google Scholar] [CrossRef] [PubMed]
  18. Liu, J.; Liu, X.; Li, Y.; Quan, J.; Wei, S.; An, S.; Yang, R.; Liu, J. The Association of Neutrophil to Lymphocyte Ratio, Mean Platelet Volume, and Platelet Distribution Width with Diabetic Retinopathy and Nephropathy: A Meta-Analysis. Biosci. Rep. 2018, 38, BSR20180172. [Google Scholar] [CrossRef]
  19. Liu, N.; Sheng, J.; Pan, T.; Wang, Y. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Are Associated with Lower Extremity Vascular Lesions in Chinese Patients with Type 2 Diabetes. Clin. Lab. 2019, 65, 180804. [Google Scholar] [CrossRef]
  20. Akbas, E.M.; Demirtas, L.; Ozcicek, A.; Timuroglu, A.; Bakirci, E.M.; Hamur, H.; Ozcicek, F.; Turkmen, K. Association of Epicardial Adipose Tissue, Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio with Diabetic Nephropathy. Int. J. Clin. Exp. Med. 2014, 7, 1794–1801. [Google Scholar]
  21. Ciray, H.; Aksoy, A.H.; Ulu, N.; Çizmecioğlu, A.; Gaipov, A.; Solak, Y. Nephropathy, but Not Angiographically Proven Retinopathy, Is Associated with Neutrophil to Lymphocyte Ratio in Patients with Type 2 Diabetes. Exp. Clin. Endocrinol. Diabetes 2015, 123, 267–271. [Google Scholar] [CrossRef] [PubMed]
  22. Wang, R.; Zhang, J.; Li, Y.; Liu, T.; Yu, K. Neutrophil-Lymphocyte Ratio Is Associated with Arterial Stiffness in Diabetic Retinopathy in Type 2 Diabetes. J. Diabetes Complicat. 2015, 29, 245–249. [Google Scholar] [CrossRef] [PubMed]
  23. Ulu, S.M.; Dogan, M.; Ahsen, A.; Altug, A.; Demir, K.; Acartürk, G.; Inan, S. Neutrophil-to-Lymphocyte Ratio as a Quick and Reliable Predictive Marker to Diagnose the Severity of Diabetic Retinopathy. Diabetes Technol. Ther. 2013, 15, 942–947. [Google Scholar] [CrossRef]
  24. Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). Lancet 1998, 352, 837–853. [CrossRef]
  25. Diabetes Control and Complications Trial Research Group; Nathan, D.M.; Genuth, S.; Lachin, J.; Cleary, P.; Crofford, O.; Davis, M.; Rand, L.; Siebert, C. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977–986. [Google Scholar] [CrossRef] [PubMed]
  26. Brownlee, M. Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature 2001, 414, 813–820. [Google Scholar] [CrossRef]
  27. Ridker, P.M.; Cushman, M.; Stampfer, M.J.; Tracy, R.P.; Hennekens, C.H. Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease. Circulation 1998, 97, 425–428. [Google Scholar] [CrossRef]
  28. Schaper, N.C.; Nabuurs-Franssen, M.H.; Huijberts, M.S. Peripheral Vascular Disease and Type 2 Diabetes Mellitus. Diabetes Metab. Res. Rev. 2000, 16 (Suppl. S1), S11–S15. [Google Scholar] [CrossRef]
  29. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. JAMA 2001, 286, 327–334. [Google Scholar] [CrossRef]
  30. Pickup, J.C.; Chusney, G.D.; Thomas, S.M.; Burt, D. Plasma Interleukin-6, Tumour Necrosis Factor Alpha and Blood Cytokine Production in Type 2 Diabetes. Life Sci. 2000, 67, 291–300. [Google Scholar] [CrossRef]
  31. Ross, R. Atherosclerosis Is an Inflammatory Disease. Am. Heart J. 1999, 138, S419–S420. [Google Scholar] [CrossRef]
  32. Yuuki, T.; Kanda, T.; Kimura, Y.; Kotajima, N.; Tamura, J.; Kobayashi, I.; Kishi, S. Inflammatory Cytokines in Vitreous Fluid and Serum of Patients with Diabetic Vitreoretinopathy. J. Diabetes Complicat. 2001, 15, 257–259. [Google Scholar] [CrossRef]
  33. Schröder, S.; Palinski, W.; Schmid-Schönbein, G.W. Activated Monocytes and Granulocytes, Capillary Nonperfusion, and Neovascularization in Diabetic Retinopathy. Am. J. Pathol. 1991, 139, 81–100. [Google Scholar] [PubMed]
  34. Chibber, R.; Ben-Mahmud, B.; Coppini, D.; Christ, E.; Kohner, E. Activity of the Glycosylating Enzyme, Core 2 GlcNAc (Β1,6) Transferase, Is Higher in Polymorphonuclear Leukocytes from Diabetic Patients Compared with Age-Matched Control Subjects: Relevance to Capillary Occlusion in Diabetic Retinopathy. Diabetes 2000, 49, 1724–1730. [Google Scholar] [CrossRef] [PubMed]
  35. Kasza, M.; Meleg, J.; Vardai, J.; Nagy, B.; Szalai, E.; Damjanovich, J.; Csutak, A.; Ujhelyi, B.; Nagy, V. Plasma E-Selectin Levels Can Play a Role in the Development of Diabetic Retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2017, 255, 25–30. [Google Scholar] [CrossRef] [PubMed]
  36. Limb, G.A.; Hickman-Casey, J.; Hollifield, R.D.; Chignell, A.H. Vascular Adhesion Molecules in Vitreous from Eyes with Proliferative Diabetic Retinopathy. Investig. Ophthalmol. Vis. Sci. 1999, 40, 2453–2457. [Google Scholar]
  37. Miyamoto, K.; Khosrof, S.; Bursell, S.E.; Rohan, R.; Murata, T.; Clermont, A.C.; Aiello, L.P.; Ogura, Y.; Adamis, A.P. Prevention of Leukostasis and Vascular Leakage in Streptozotocin-Induced Diabetic Retinopathy via Intercellular Adhesion Molecule-1 Inhibition. Proc. Natl. Acad. Sci. USA 1999, 96, 10836–10841. [Google Scholar] [CrossRef]
  38. Suzuki, Y.; Nakazawa, M.; Suzuki, K.; Yamazaki, H.; Miyagawa, Y. Expression Profiles of Cytokines and Chemokines in Vitreous Fluid in Diabetic Retinopathy and Central Retinal Vein Occlusion. Jpn. J. Ophthalmol. 2011, 55, 256–263. [Google Scholar] [CrossRef]
  39. Koleva-Georgieva, D.N.; Sivkova, N.P.; Terzieva, D. Serum Inflammatory Cytokines IL-1beta, IL-6, TNF-Alpha and VEGF Have Influence on the Development of Diabetic Retinopathy. Folia Med. 2011, 53, 44–50. [Google Scholar] [CrossRef]
  40. Boss, J.D.; Singh, P.K.; Pandya, H.K.; Tosi, J.; Kim, C.; Tewari, A.; Juzych, M.S.; Abrams, G.W.; Kumar, A. Assessment of Neurotrophins and Inflammatory Mediators in Vitreous of Patients with Diabetic Retinopathy. Investig. Ophthalmol. Vis. Sci. 2017, 58, 5594–5603. [Google Scholar] [CrossRef]
  41. Williams, G.; Pickup, J.C. Handbook of Diabetes; Wiley: Hoboken, NJ, USA, 2004; ISBN 978-1-4051-2052-4. [Google Scholar]
  42. Gheith, O.; Farouk, N.; Nampoory, N.; Halim, M.A.; Al-Otaibi, T. Diabetic Kidney Disease: World Wide Difference of Prevalence and Risk Factors. J. Nephropharmacology 2015, 5, 49–56. [Google Scholar] [CrossRef]
  43. Stenvinkel, P. Chronic Kidney Disease: A Public Health Priority and Harbinger of Premature Cardiovascular Disease. J. Intern. Med. 2010, 268, 456–467. [Google Scholar] [CrossRef]
  44. Tavafi, M. Diabetic Nephropathy and Antioxidants. J. Nephropathol. 2013, 2, 20–27. [Google Scholar] [CrossRef]
  45. Navarro, J.F.; Mora, C. Role of Inflammation in Diabetic Complications. Nephrol. Dial. Transplant. 2005, 20, 2601–2604. [Google Scholar] [CrossRef]
  46. Suzuki, D.; Miyazaki, M.; Naka, R.; Koji, T.; Yagame, M.; Jinde, K.; Endoh, M.; Nomoto, Y.; Sakai, H. In Situ Hybridization of Interleukin 6 in Diabetic Nephropathy. Diabetes 1995, 44, 1233–1238. [Google Scholar] [CrossRef]
  47. Wong, C.K.; Ho, A.W.Y.; Tong, P.C.Y.; Yeung, C.Y.; Kong, A.P.S.; Lun, S.W.M.; Chan, J.C.N.; Lam, C.W.K. Aberrant Activation Profile of Cytokines and Mitogen-Activated Protein Kinases in Type 2 Diabetic Patients with Nephropathy. Clin. Exp. Immunol. 2007, 149, 123–131. [Google Scholar] [CrossRef]
  48. Lim, A.K.H.; Tesch, G.H. Inflammation in Diabetic Nephropathy. Mediat. Inflamm. 2012, 2012, 146154. [Google Scholar] [CrossRef]
  49. Shang, J.; Wang, L.; Zhang, Y.; Zhang, S.; Ning, L.; Zhao, J.; Cheng, G.; Liu, D.; Xiao, J.; Zhao, Z. Chemerin/ChemR23 Axis Promotes Inflammation of Glomerular Endothelial Cells in Diabetic Nephropathy. J. Cell. Mol. Med. 2019, 23, 3417–3428. [Google Scholar] [CrossRef]
  50. Awad, A.S.; Kinsey, G.R.; Khutsishvili, K.; Gao, T.; Bolton, W.K.; Okusa, M.D. Monocyte/Macrophage Chemokine Receptor CCR2 Mediates Diabetic Renal Injury. Am. J. Physiol.-Ren. Physiol. 2011, 301, F1358–F1366. [Google Scholar] [CrossRef]
  51. Doupis, J.; Lyons, T.E.; Wu, S.; Gnardellis, C.; Dinh, T.; Veves, A. Microvascular Reactivity and Inflammatory Cytokines in Painful and Painless Peripheral Diabetic Neuropathy. J. Clin. Endocrinol. Metab. 2009, 94, 2157–2163. [Google Scholar] [CrossRef]
  52. Magrinelli, F.; Briani, C.; Romano, M.; Ruggero, S.; Toffanin, E.; Triolo, G.; Peter, G.C.; Praitano, M.; Lauriola, M.F.; Zanette, G.; et al. The Association between Serum Cytokines and Damage to Large and Small Nerve Fibers in Diabetic Peripheral Neuropathy. J. Diabetes Res. 2015, 2015, 547834. [Google Scholar] [CrossRef]
  53. Jin, H.Y.; Park, T.S. Role of Inflammatory Biomarkers in Diabetic Peripheral Neuropathy. J. Diabetes Investig. 2018, 9, 1016–1018. [Google Scholar] [CrossRef]
  54. Herder, C.; Kannenberg, J.M.; Huth, C.; Carstensen-Kirberg, M.; Rathmann, W.; Koenig, W.; Heier, M.; Püttgen, S.; Thorand, B.; Peters, A.; et al. Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Diabetes Care 2017, 40, 569–576. [Google Scholar] [CrossRef]
  55. Eshcol, J.; Jebarani, S.; Anjana, R.M.; Mohan, V.; Pradeepa, R. Prevalence, Incidence and Progression of Peripheral Arterial Disease in Asian Indian Type 2 Diabetic Patients. J. Diabetes Complicat. 2014, 28, 627–631. [Google Scholar] [CrossRef]
  56. Lekshmi Narayanan, R.M.; Koh, W.P.; Phang, J.; Subramaniam, T. Peripheral Arterial Disease in Community-Based Patients with Diabetes in Singapore: Results from a Primary Healthcare Study. Ann. Acad. Med. Singapore 2010, 39, 525–527. [Google Scholar] [CrossRef]
  57. Rhee, S.Y.; Guan, H.; Liu, Z.M.; Cheng, S.W.-K.; Waspadji, S.; Palmes, P.; Tai, T.Y.; Suwanwalaikorn, S.; Kim, Y.S.; PAD-SEARCH Study Group. Multi-Country Study on the Prevalence and Clinical Features of Peripheral Arterial Disease in Asian Type 2 Diabetes Patients at High Risk of Atherosclerosis. Diabetes Res. Clin. Pract. 2007, 76, 82–92. [Google Scholar] [CrossRef]
  58. Merino, J.; Planas, A.; Elosua, R.; de Moner, A.; Gasol, A.; Contreras, C.; Vidal-Barraquer, F.; Clarà, A. Incidence and Risk Factors of Peripheral Arterial Occlusive Disease in a Prospective Cohort of 700 Adult Elderly Men Followed for 5 Years. World J. Surg. 2010, 34, 1975–1979. [Google Scholar] [CrossRef]
  59. Velescu, A.; Clara, A.; Peñafiel, J.; Grau, M.; Degano, I.R.; Martí, R.; Ramos, R.; Marrugat, J.; Elosua, R. Peripheral Arterial Disease Incidence and Associated Risk Factors in a Mediterranean Population-Based Cohort. The REGICOR Study. Eur. J. Vasc. Endovasc. Surg. Off. J. Eur. Soc. Vasc. Surg. 2016, 51, 696–705. [Google Scholar] [CrossRef]
  60. Arbănași, E.M.; Halmaciu, I.; Kaller, R.; Mureșan, A.V.; Arbănași, E.M.; Suciu, B.A.; Coșarcă, C.M.; Cojocaru, I.I.; Melinte, R.M.; Russu, E. Systemic Inflammatory Biomarkers and Chest CT Findings as Predictors of Acute Limb Ischemia Risk, Intensive Care Unit Admission, and Mortality in COVID-19 Patients. Diagnostics 2022, 12, 2379. [Google Scholar] [CrossRef]
  61. Halmaciu, I.; Arbănași, E.M.; Kaller, R.; Mureșan, A.V.; Arbănași, E.M.; Bacalbasa, N.; Suciu, B.A.; Cojocaru, I.I.; Runcan, A.I.; Grosu, F.; et al. Chest CT Severity Score and Systemic Inflammatory Biomarkers as Predictors of the Need for Invasive Mechanical Ventilation and of COVID-19 Patients’ Mortality. Diagnostics 2022, 12, 2089. [Google Scholar] [CrossRef]
  62. Kaller, R.; Arbănași, E.M.; Mureșan, A.V.; Voidăzan, S.; Arbănași, E.M.; Horváth, E.; Suciu, B.A.; Hosu, I.; Halmaciu, I.; Brinzaniuc, K.; et al. The Predictive Value of Systemic Inflammatory Markers, the Prognostic Nutritional Index, and Measured Vessels’ Diameters in Arteriovenous Fistula Maturation Failure. Life 2022, 12, 1447. [Google Scholar] [CrossRef] [PubMed]
  63. Mureșan, A.V.; Hălmaciu, I.; Arbănași, E.M.; Kaller, R.; Arbănași, E.M.; Budișcă, O.A.; Melinte, R.M.; Vunvulea, V.; Filep, R.C.; Mărginean, L.; et al. Prognostic Nutritional Index, Controlling Nutritional Status (CONUT) Score, and Inflammatory Biomarkers as Predictors of Deep Vein Thrombosis, Acute Pulmonary Embolism, and Mortality in COVID-19 Patients. Diagnostics 2022, 12, 2757. [Google Scholar] [CrossRef] [PubMed]
  64. Arbănași, E.M.; Mureșan, A.V.; Coșarcă, C.M.; Kaller, R.; Bud, T.I.; Hosu, I.; Voidăzan, S.T.; Arbănași, E.M.; Russu, E. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Impact on Predicting Outcomes in Patients with Acute Limb Ischemia. Life 2022, 12, 822. [Google Scholar] [CrossRef] [PubMed]
  65. Melinte, R.M.; Arbănași, E.M.; Blesneac, A.; Zolog, D.N.; Kaller, R.; Mureșan, A.V.; Arbănași, E.M.; Melinte, I.M.; Niculescu, R.; Russu, E. Inflammatory Biomarkers as Prognostic Factors of Acute Deep Vein Thrombosis Following the Total Knee Arthroplasty. Medicina 2022, 58, 1502. [Google Scholar] [CrossRef] [PubMed]
  66. Russu, E.; Mureșan, A.V.; Arbănași, E.M.; Kaller, R.; Hosu, I.; Voidăzan, S.; Arbănași, E.M.; Coșarcă, C.M. The Predictive Role of NLR and PLR in Outcome and Patency of Lower Limb Revascularization in Patients with Femoropopliteal Disease. J. Clin. Med. 2022, 11, 2620. [Google Scholar] [CrossRef] [PubMed]
  67. Arbănași, E.M.; Mureșan, A.V.; Arbănași, E.M.; Kaller, R.; Cojocaru, I.I.; Coșarcă, C.M.; Russu, E. The Neutrophil-to-Lymphocyte Ratio’s Predictive Utility in Acute Pulmonary Embolism: Systematic Review. J. Cardiovasc. Emergencies 2022, 8, 25–30. [Google Scholar] [CrossRef]
  68. Niculescu, R.; Russu, E.; Arbănași, E.M.; Kaller, R.; Arbănași, E.M.; Melinte, R.M.; Coșarcă, C.M.; Cocuz, I.G.; Sabău, A.H.; Tinca, A.C.; et al. Carotid Plaque Features and Inflammatory Biomarkers as Predictors of Restenosis and Mortality Following Carotid Endarterectomy. Int. J. Environ. Res. Public. Health 2022, 19, 13934. [Google Scholar] [CrossRef]
  69. Mureșan, A.V.; Russu, E.; Arbănași, E.M.; Kaller, R.; Hosu, I.; Arbănași, E.M.; Voidăzan, S.T. The Predictive Value of NLR, MLR, and PLR in the Outcome of End-Stage Kidney Disease Patients. Biomedicines 2022, 10, 1272. [Google Scholar] [CrossRef]
  70. Roumeliotis, S.; Neofytou, I.E.; Maassen, C.; Lux, P.; Kantartzi, K.; Papachristou, E.; Schurgers, L.J.; Liakopoulos, V. Association of Red Blood Cell Distribution Width and Neutrophil-to-Lymphocyte Ratio with Calcification and Cardiovascular Markers in Chronic Kidney Disease. Metabolites 2023, 13, 303. [Google Scholar] [CrossRef]
  71. Caicedo, D.; Alvarez, C.V.; Perez-Romero, S.; Devesa, J. The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF-α Hypothesis. Biomedicines 2022, 10, 489. [Google Scholar] [CrossRef]
  72. Taurino, M.; Aloisi, F.; Del Porto, F.; Nespola, M.; Dezi, T.; Pranteda, C.; Rizzo, L.; Sirignano, P. Neutrophil-to-Lymphocyte Ratio Could Predict Outcome in Patients Presenting with Acute Limb Ischemia. J. Clin. Med. 2021, 10, 4343. [Google Scholar] [CrossRef] [PubMed]
  73. Serra, R.; Ielapi, N.; Licastro, N.; Provenzano, M.; Andreucci, M.; Bracale, U.M.; Jiritano, F.; de Franciscis, S.; Mastroroberto, P.; Serraino, G.F. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review. Rev. Recent Clin. Trials 2021, 16, 173–179. [Google Scholar] [CrossRef] [PubMed]
  74. Wachsmann-Maga, A.; Kaszuba, M.; Maga, M.; Włodarczyk, A.; Krężel, J.; Kaczmarczyk, P.; Bogucka, K.; Maga, P. Leukotrienes in the Atherosclerotic Cardiovascular Diseases—A Systematic Review. Acta Angiol. 2022, 28, 147–153. [Google Scholar] [CrossRef]
  75. Wachsmann, A.; Maga, M.; Cebeńko, M.; Schönborn, M.; Olszewska, M.; Blukacz, M.; Maga, P.; Trynkiewicz, A. Impact of Pre-Operative Glycated Haemoglobin A1C Level on 1-Year Outcomes of Endovascular Treatment in Patients with Critical Limb Ischemia in the Course of Diabetes Mellitus. Folia Med. Cracoviensia 2019, 59, 49–60. [Google Scholar]
Life 13 01861 g001
Figure 1. Plot representation of the dispersion of data of the correlation between duration of diabetes (years) and (A) MLR (r = 0.331, p < 0.001), (B) NLR (r = 0.517, p < 0.001), (C) PLR (r = 0.296, p < 0.001), (D) SII (r = 0.413, p < 0.001), (E) BMI (r = 0.241, p < 0.001), and (F) HbA1C (r = 0.489, p < 0.001).
Figure 1. Plot representation of the dispersion of data of the correlation between duration of diabetes (years) and (A) MLR (r = 0.331, p < 0.001), (B) NLR (r = 0.517, p < 0.001), (C) PLR (r = 0.296, p < 0.001), (D) SII (r = 0.413, p < 0.001), (E) BMI (r = 0.241, p < 0.001), and (F) HbA1C (r = 0.489, p < 0.001).
Life 13 01861 g001
Life 13 01861 g002
Figure 2. The ROC curve graphics regarding the prediction of SA in PN patients for (A) MLR (AUC:0.689, p < 0.0001), (B) NLR (AUC:0.820, p < 0.0001), (C) PLR (AUC:0.751, p < 0.0001), (D) SII (AUC:0.759, p < 0.0001), (E) BMI (AUC:0.793, p < 0.0001), (F) HbA1C (AUC:0.857, p < 0.0001), (G) duration of diabetes (AUC:0.812 p < 0.0001), and (H) admission glucose (AUC:0.899, p < 0.0001).
Figure 2. The ROC curve graphics regarding the prediction of SA in PN patients for (A) MLR (AUC:0.689, p < 0.0001), (B) NLR (AUC:0.820, p < 0.0001), (C) PLR (AUC:0.751, p < 0.0001), (D) SII (AUC:0.759, p < 0.0001), (E) BMI (AUC:0.793, p < 0.0001), (F) HbA1C (AUC:0.857, p < 0.0001), (G) duration of diabetes (AUC:0.812 p < 0.0001), and (H) admission glucose (AUC:0.899, p < 0.0001).
Life 13 01861 g002
Table 1. The variables analyzed in this study presented for all patients and compared according to the presence of AS.
Table 1. The variables analyzed in this study presented for all patients and compared according to the presence of AS.
VariablesAll Patients
n = 198		No-SA
n = 126		SA
n = 72		p-Value
Age mean ± SD (min–max)64.36 ± 10.18
(35–87)		62.96 ± 9.99
(35–86)		66.80 ± 10.13
(42–87)		0.01
Male/Female gender no. (%)93 (46.97%)
105 (53.03%)		53 (42.06%)
73 (57.94%)		40 (55.56%)
32 (44.44%)		0.06
Comorbidities and Risk factors, no. (%)
Arterial Hypertension183 (92.42%)116 (92.06%)67 (93.05%)0.79
Ischemic Heart Disease107 (54.04%)61 (48.41%)46 (63.88%)0.03
Chronic Venous Insufficiency89 (44.94%)61 (48.41%)28 (38.88%)0.19
Malignancy28 (14.14%)20 (15.87%)8 (11.11%)0.35
Active Smoking81 (40.9%)25 (34.72%)56 (44.44%)0.18
History of Stroke11 (5.55%)7 (5.55%)4 (5.55%)NS
History of Myocardial Infraction18 (9.09%)7 (5.55%)11 (15.27%)0.02
End Stage Kidney Disease28 (14.14%)15 (11.9%)13 (18.05%)0.23
Diabetic Retinopathy54 (27.27%)30 (23.80%)24 (33.33%)0.14
Diabetic Nephropathy40 (20.2%)19 (15.07%)21 (29.16%)0.01
Anthropometric Characteristics, median [Q1–Q3]
BMI (kg/m2)29.32 [23.92–33.68]25.81 [21.16–30.45]32 [30.1–35.36]<0.0001
Abdominal circumferential (cm)110 [100–120]109 [100–118.25]112 [101–121]0.052
Duration of Diabetes (years)10 [5–15]7 [4–11]15 [11.75–22]<0.0001
Laboratory Findings, median [Q1–Q3]
HbA1C (%)6.83 [6–8.3]6.2 [5.8–7]8.55 [7.3–11.2]<0.0001
Admission Glucose (mg/dL)141 [114–199.75]122 [101.25–143]218 [174–271.25]<0.0001
Cholesterol (mg/dL)167.3 [132–203.47]154.15 [122.1–190.85]189.4 [157.3–209.32]<0.0001
Triglyceride (mg/dL)162.1 [118.32–241.72]152 [116.15–237.9]177.6 [120.55–248.9]0.12
AST (IU/L)21 [15.9–30.8]22.45 [16.15–31.97]19.2 [15.7–27.17]0.04
ALT (IU/L)21.95 [15.87–35.52]23.15 [18–41]19.7 [14.2–30.92]0.007
GGT (IU/L)34 [23–72]37 [21–75]31.5 [23–62]0.26
BUN (mg/dL)41.55 [32.42–56.67]39.45 [30.45–56.35]43 [35.57–56.77]0.09
Creatinine (mg/dL)0.95 [0.77–1.29]0.91 [0.73–1.23]1.02 [0.84–1.38]0.02
Hemoglobin (g/dL)13.5 [12.3–14.6]13.3 [12.3–14.47]13.5 [12.47–14.87]0.18
Hematocrit %40.65 [37.22–43.65]40.55 [37.1–43.5]40.7 [37.27–43.72]0.35
WBC8.06 [6.63–9.78]8.18 [6.64–9.67]7.69 [6.32–9.84]0.21
Neutrophil4.8 [3.83–6.12]4.66 [3.82–5.79]5.22 [3.92–7.01]0.02
Monocyte0.61 [0.51–0.76]0.63 [0.53–0.77]0.59 [0.48–0.71]0.03
Lymphocyte2.04 [1.53–2.65]2.34 [1.93–2.97]1.67 [1.31–1.98]<0.0001
PLT237 [200.25–290.75]246.5 [205.25–290.75]231.5 [198.5–201]0.20
NLR2.24 [1.77–3.15]1.95 [1.60–2.50]3.16 [2.41–4.66]<0.0001
MLR0.30 [0.22–0.40]0.27 [0.21–0.35]0.35 [0.27–0.46]<0.0001
PLR116.52 [91.2–162.7]103.26 [84.4–128.89]157.64 [113.28–194.59]<0.0001
SII575.5 [399.9–838.7]468.6 [363.2–631.1]802.9 [577.1–1004.9]<0.0001
Table 2. The optimal cut-off value and the characteristics of all the markers analyzed with the ROC curve.
Table 2. The optimal cut-off value and the characteristics of all the markers analyzed with the ROC curve.
VariablesCut-OffAUCStd. Error95% CISensitivitySpecificityp-Value
Subclinical Atherosclerosis of Lower Limb
MLR0.330.6890.0390.613–0.76559.7%71.4%<0.0001
NLR2.530.8200.0310.759–0.88173.6%77%<0.0001
PLR137.210.7510.0360.680–0.82162.5%82.5%<0.0001
SII615.910.7590.0360.688–0.82968.1%73.8%<0.0001
BMI30.870.7930.0310.732–0.85468.1%79.4%<0.0001
HbA1C7.450.8570.0280.802–0.91173.6%82.5%<0.0001
Duration of Diabetes9.50.8120.0320.749–0.87583.3%65.1%<0.0001
Admission Glucose level161.50.8990.0250.850–0.94880.6%85.7%<0.0001
Table 3. Predictors of subclinical atherosclerosis in DN patients.
Table 3. Predictors of subclinical atherosclerosis in DN patients.
Subclinical Atherosclerosis
OR95% CIp-Value
Demographic Characteristics
Age2.581.79–5.93<0.001
Male2.301.26–4.190.006
Comorbidities and Risk factors
Ischemic Heart Disease1.570.85–2.180.11
History of Myocardial Infraction1.260.76–2.870.20
Diabetic Nephropathy1.950.93–4.550.052
Tobacco1.330.70–3.460.18
Anthropometric Characteristics
BMI (kg/m2)7.713.57–14.90<0.001
Abdominal circumferential (cm)1.860.84–3.780.06
Duration of Diabetes (years)8.654.35–16.78<0.001
Inflammatory Markers
NLR7.463.38–13.58<0.001
MLR4.631.99–9.12<0.001
PLR5.892.62–11.88<0.001
SII6.092.68–12.16<0.001
Diabetes Controlling Status
HbA1C10.48.27–28.74<0.001
Admission Glucose10.788.69–32.45<0.001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mureșan, A.V.; Tomac, A.; Opriș, D.R.; Bandici, B.C.; Coșarcă, C.M.; Covalcic, D.C.; Hălmaciu, I.; Akácsos-Szász, O.-Z.; Rădulescu, F.; Lázár, K.; et al. Inflammatory Markers Used as Predictors of Subclinical Atherosclerosis in Patients with Diabetic Polyneuropathy. Life 2023, 13, 1861. https://doi.org/10.3390/life13091861

AMA Style

Mureșan AV, Tomac A, Opriș DR, Bandici BC, Coșarcă CM, Covalcic DC, Hălmaciu I, Akácsos-Szász O-Z, Rădulescu F, Lázár K, et al. Inflammatory Markers Used as Predictors of Subclinical Atherosclerosis in Patients with Diabetic Polyneuropathy. Life. 2023; 13(9):1861. https://doi.org/10.3390/life13091861

Chicago/Turabian Style

Mureșan, Adrian Vasile, Alexandru Tomac, Diana Roxana Opriș, Bogdan Corneliu Bandici, Cătălin Mircea Coșarcă, Diana Carina Covalcic, Ioana Hălmaciu, Orsolya-Zsuzsa Akácsos-Szász, Flavia Rădulescu, Krisztina Lázár, and et al. 2023. "Inflammatory Markers Used as Predictors of Subclinical Atherosclerosis in Patients with Diabetic Polyneuropathy" Life 13, no. 9: 1861. https://doi.org/10.3390/life13091861

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop